Treatment of chronic hepatitis C with recombinant interferon alfa-2b
In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasi...
Gespeichert in:
| Veröffentlicht in: | Gut 1993, Vol.34 (2), p.S128-S129 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S129 |
|---|---|
| container_issue | 2 |
| container_start_page | S128 |
| container_title | Gut |
| container_volume | 34 |
| creator | PIAZZA, M ORLANDO, R TOSONE, G TISEO, D CONTE, M. C. D MINERVINI, F SANTORO, G SCORDINO, F VITALE, D |
| description | In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients. |
| doi_str_mv | 10.1136/gut.34.2_Suppl.S128 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1374037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75807688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-c7ada3c6648b13ed03c16dbfc034c3b3d3bb407c4fe9bcce5b0a5d6f16d503cf3</originalsourceid><addsrcrecordid>eNpVkE1P3DAQhi1UBFvgF1RIOVS9ZbEzTuxcKlXbllZC4gCcLXtis67yVdsp4t9jRLQqpzm8z7wzegj5xOiWMWiuHpe0Bb6t1N0yz_32jlXyiGwYb2QJlZQfyIZSJspa8PaUfIzxD6VUypadkBMJjHPRbsj3-2B1GuyYiskVuA_T6LHY21knn3wsdsWTT_siWJwG40edOT8mG5zNZKF7p8vKnJNjp_toL9Z5Rh5-_rjf_Spvbq9_777dlMirNpUodKcBm4ZLw8B2FJA1nXFIgSMY6MAYTgVyZ1uDaGtDdd01LkN1Zh2cka9vvfNiBtth_jroXs3BDzo8q0l79T4Z_V49Tv8UA8EpiFzwZS0I09_FxqQGH9H2vR7ttEQlaklFI2UG4Q3EMMUYrDscYVS9yldZvgKuVvnqVX7euvz_v8POajvnn9dcR8zugh7RxwPGRQ1QNfACoUuSkA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75807688</pqid></control><display><type>article</type><title>Treatment of chronic hepatitis C with recombinant interferon alfa-2b</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>PIAZZA, M ; ORLANDO, R ; TOSONE, G ; TISEO, D ; CONTE, M. C. D ; MINERVINI, F ; SANTORO, G ; SCORDINO, F ; VITALE, D</creator><creatorcontrib>PIAZZA, M ; ORLANDO, R ; TOSONE, G ; TISEO, D ; CONTE, M. C. D ; MINERVINI, F ; SANTORO, G ; SCORDINO, F ; VITALE, D</creatorcontrib><description>In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>EISSN: 1458-3288</identifier><identifier>DOI: 10.1136/gut.34.2_Suppl.S128</identifier><identifier>PMID: 8314479</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>London: BMJ</publisher><subject>Adolescent ; Adult ; Alanine Transaminase - blood ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Drug Administration Schedule ; Female ; Hepatitis C - enzymology ; Hepatitis C - therapy ; Hepatitis, Chronic - therapy ; Humans ; Injections, Intramuscular ; Injections, Intravenous ; Interferon alpha-2 ; Interferon-alpha - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recombinant Proteins</subject><ispartof>Gut, 1993, Vol.34 (2), p.S128-S129</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-c7ada3c6648b13ed03c16dbfc034c3b3d3bb407c4fe9bcce5b0a5d6f16d503cf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374037/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374037/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,309,310,314,727,780,784,789,790,885,4024,4050,4051,23930,23931,25140,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4753326$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8314479$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PIAZZA, M</creatorcontrib><creatorcontrib>ORLANDO, R</creatorcontrib><creatorcontrib>TOSONE, G</creatorcontrib><creatorcontrib>TISEO, D</creatorcontrib><creatorcontrib>CONTE, M. C. D</creatorcontrib><creatorcontrib>MINERVINI, F</creatorcontrib><creatorcontrib>SANTORO, G</creatorcontrib><creatorcontrib>SCORDINO, F</creatorcontrib><creatorcontrib>VITALE, D</creatorcontrib><title>Treatment of chronic hepatitis C with recombinant interferon alfa-2b</title><title>Gut</title><addtitle>Gut</addtitle><description>In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Hepatitis C - enzymology</subject><subject>Hepatitis C - therapy</subject><subject>Hepatitis, Chronic - therapy</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Injections, Intravenous</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins</subject><issn>0017-5749</issn><issn>1468-3288</issn><issn>1458-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1P3DAQhi1UBFvgF1RIOVS9ZbEzTuxcKlXbllZC4gCcLXtis67yVdsp4t9jRLQqpzm8z7wzegj5xOiWMWiuHpe0Bb6t1N0yz_32jlXyiGwYb2QJlZQfyIZSJspa8PaUfIzxD6VUypadkBMJjHPRbsj3-2B1GuyYiskVuA_T6LHY21knn3wsdsWTT_siWJwG40edOT8mG5zNZKF7p8vKnJNjp_toL9Z5Rh5-_rjf_Spvbq9_777dlMirNpUodKcBm4ZLw8B2FJA1nXFIgSMY6MAYTgVyZ1uDaGtDdd01LkN1Zh2cka9vvfNiBtth_jroXs3BDzo8q0l79T4Z_V49Tv8UA8EpiFzwZS0I09_FxqQGH9H2vR7ttEQlaklFI2UG4Q3EMMUYrDscYVS9yldZvgKuVvnqVX7euvz_v8POajvnn9dcR8zugh7RxwPGRQ1QNfACoUuSkA</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>PIAZZA, M</creator><creator>ORLANDO, R</creator><creator>TOSONE, G</creator><creator>TISEO, D</creator><creator>CONTE, M. C. D</creator><creator>MINERVINI, F</creator><creator>SANTORO, G</creator><creator>SCORDINO, F</creator><creator>VITALE, D</creator><general>BMJ</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>1993</creationdate><title>Treatment of chronic hepatitis C with recombinant interferon alfa-2b</title><author>PIAZZA, M ; ORLANDO, R ; TOSONE, G ; TISEO, D ; CONTE, M. C. D ; MINERVINI, F ; SANTORO, G ; SCORDINO, F ; VITALE, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-c7ada3c6648b13ed03c16dbfc034c3b3d3bb407c4fe9bcce5b0a5d6f16d503cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Hepatitis C - enzymology</topic><topic>Hepatitis C - therapy</topic><topic>Hepatitis, Chronic - therapy</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Injections, Intravenous</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PIAZZA, M</creatorcontrib><creatorcontrib>ORLANDO, R</creatorcontrib><creatorcontrib>TOSONE, G</creatorcontrib><creatorcontrib>TISEO, D</creatorcontrib><creatorcontrib>CONTE, M. C. D</creatorcontrib><creatorcontrib>MINERVINI, F</creatorcontrib><creatorcontrib>SANTORO, G</creatorcontrib><creatorcontrib>SCORDINO, F</creatorcontrib><creatorcontrib>VITALE, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PIAZZA, M</au><au>ORLANDO, R</au><au>TOSONE, G</au><au>TISEO, D</au><au>CONTE, M. C. D</au><au>MINERVINI, F</au><au>SANTORO, G</au><au>SCORDINO, F</au><au>VITALE, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of chronic hepatitis C with recombinant interferon alfa-2b</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>1993</date><risdate>1993</risdate><volume>34</volume><issue>2</issue><spage>S128</spage><epage>S129</epage><pages>S128-S129</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><eissn>1458-3288</eissn><coden>GUTTAK</coden><abstract>In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.</abstract><cop>London</cop><pub>BMJ</pub><pmid>8314479</pmid><doi>10.1136/gut.34.2_Suppl.S128</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-5749 |
| ispartof | Gut, 1993, Vol.34 (2), p.S128-S129 |
| issn | 0017-5749 1468-3288 1458-3288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1374037 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Adult Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Drug Administration Schedule Female Hepatitis C - enzymology Hepatitis C - therapy Hepatitis, Chronic - therapy Humans Injections, Intramuscular Injections, Intravenous Interferon alpha-2 Interferon-alpha - administration & dosage Male Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant Proteins |
| title | Treatment of chronic hepatitis C with recombinant interferon alfa-2b |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T03%3A22%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20chronic%20hepatitis%20C%20with%20recombinant%20interferon%20alfa-2b&rft.jtitle=Gut&rft.au=PIAZZA,%20M&rft.date=1993&rft.volume=34&rft.issue=2&rft.spage=S128&rft.epage=S129&rft.pages=S128-S129&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gut.34.2_Suppl.S128&rft_dat=%3Cproquest_pubme%3E75807688%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75807688&rft_id=info:pmid/8314479&rfr_iscdi=true |